Energy Focus (NASDAQ:EFOI) today reported its financial results for the fourth quarter and full year ended December 31, 2025, reflecting a period of narrowed losses and continued focus on high-specification lighting solutions.
Trian Fund Management and General Catalyst Group Management today announced a definitive amendment to their merger agreement with Janus Henderson Group (NYSE:JHG), raising the acquisition price to $52 per share in cash.
Sanara MedTech (NASDAQ:SMTI) today announced its financial results for the fourth quarter and full year ended December 31, 2025, marking the first time the company has surpassed the $100 million annual revenue threshold.
Perma-Fix Environmental Services (NASDAQ:PESI) today reported financial results for the full year ended December 31, 2025, detailing a year of strategic capacity expansion and a significant buildup in high-margin service demand.
Neurogene (NASDAQ:NGNE) today reported financial results for the fourth quarter and full year ended December 31, 2025, delivering a "beat" against Wall Street’s bottom-line expectations.
LENZ Therapeutics (NASDAQ:LENZ) today reported its financial results for the fourth quarter and full year ended December 31, 2025, providing the first comprehensive look at the commercial performance of VIZZ® (aceclidine 1.44%).
Heidmar Maritime Holdings (NASDAQ:HMR) today reported its financial results for the fourth quarter and full year ended December 31, 2025, highlighting a period of rapid institutional scaling.
Ocugen (NASDAQ:OCGN) today announced positive 12-month results from its Phase 2 ArMaDa clinical trial evaluating OCU410 (AAV-hRORA), a modifier gene therapy for the treatment of Geographic Atrophy (GA) secondary to dry Age-Related Macular Degeneration (dAMD).
NRx Pharmaceuticals (NASDAQ:NRXP) today reported its financial results and operational milestones for the full year ended December 31, 2025, highlighting a successful restructuring of its balance sheet and the transition into a revenue-generating entity.
Concentrix (NASDAQ:CNXC) today reported its financial results for the fiscal first quarter ended February 28, 2026, demonstrating steady top-line expansion and a continued commitment to shareholder returns.
Core & Main (NYSE:CNM) today reported financial results for the fourth quarter and fiscal year ended February 1, 2026, showcasing a year of disciplined margin management and robust cash generation.
Fennec Pharmaceuticals (NASDAQ:FENC) today reported its financial results for the fourth quarter and full year ended December 31, 2025, highlighting a year of aggressive commercial scaling and a total recapitalization of the company’s balance sheet.
